ADA Assessment for Cell Therapies
Cell therapies are emerging as promising therapies for a variety of disease indications. The ability to detect anti-drug antibodies (ADA) is important for patients receiving cell-based therapies. However, approaches to detecting ADAs against cell-surface biotherapeutics vary, utilizing either traditional ligand binding assays or cell-based binding assays. This presentation will cover the challenges of both approaches and current industry practices.
Who Should Attend?
- Bioanalytical scientists
- Clinical pharmacologists
- Scientists working on cell therapy programs
-
Virtual
Free